Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissue

Barreca, Antonella; Bottasso, Emanuel; Veneziano, Francesca; Giarin, M.; Nocifora, Alberto; Martinetti, Nadia; Attanasio, A.; Biancone, Luigi; Benevolo, Giulia; Roccatello, Dario; Cassoni, Paola; Papotti, Mauro

doi:10.1371/journal.pone.0256306

Cited by 13 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, the use of immunohistochemistry in combination with clinical testing can help identify precursor proteins in amyloid deposits and their subtyping [13,14].…”

Section: Discussionmentioning

confidence: 99%

Nodular amyloidosis of the lung presenting as lung malignancy

et al. 2023

View full text Add to dashboard Cite

Introduction. Amyloidosis is a disease associated with the extracellular deposition of insoluble protein material called amyloid. It can be acquired or hereditary, systemic or organ-limited. Nodular pulmonary amyloidosis is defined as one or more tumefactive amyloid deposits in the lungs. Case outlines. This study presents two cases that were hospitalized at the Institute for Pulmonary Diseases to clarify the origin of lesions detected on CT scans of lung parenchyma. In the first case, in a 78-year-old woman, numerous non-calcified nodules were described on the chest CT. The patient died during hospitalization, and the autopsy revealed diffusely distributed greyish-yellow nodular lesions in the upper and middle parts of the right lung, as well as lesions in the form of partially calcified nodules in both lungs. Histological analysis of samples from macroscopically described nodules confirmed nodular amyloidosis. The patient from the second presented case is a male, 58 years old, who was operated on for rectal adenocarcinoma three years ago. A CT scan of the lung parenchyma shows a tumor nodule localized in the lower lobe and a nodular lesion localized in the upper lobe of the right lung. Histological analysis confirmed that the lesion from the lower lobe corresponds to the metastasis of colorectal cancer, while in the lesion from the upper lobe amyloid deposits were found. Conclusion. Pulmonary nodular amyloidosis is a rare condition, and because of the imaging similarities it is difficult to distinguish it from malignant nodules in the lung parenchyma. Therefore, as a part of routine practice, a definitive diagnosis of amyloidosis needs to be confirmed by tissue biopsy.

show abstract

“…Nowadays, the use of immunohistochemistry in combination with clinical testing can help identify precursor proteins in amyloid deposits and their subtyping [13,14].…”

Section: Discussionmentioning

confidence: 99%

Nodular amyloidosis of the lung presenting as lung malignancy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The technique can be applied to almost any tissue source, including nerves and fat, 24 and it can identify heavy chain as well as light chain amyloidosis 25 . Mass spectroscopy is superior to immunohistochemistry in identifying the protein subunit 26 . Cardiac amyloidosis in the presence of a monoclonal gammopathy does not necessarily mean the amyloidosis is AL.…”

Section: Disease Overviewmentioning

confidence: 99%

“…25 Mass spectroscopy is superior to immunohistochemistry in identifying the protein subunit. 26 Cardiac amyloidosis in the presence of a monoclonal gammopathy does not necessarily mean the amyloidosis is AL. Approximately 23% of wtTTR amyloid patients have a MGUS.…”

Section: Patientmentioning

confidence: 99%

Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment

Gertz

2022

American J Hematol

View full text Add to dashboard Cite

Disease overview Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include heart failure with preserved ejection fraction, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and “atypical smoldering multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).” Diagnosis Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for the diagnosis of AL amyloidosis. Invasive organ biopsy is not required in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory. The gold standard is laser capture mass spectroscopy. Prognosis N‐terminal pro–brain natriuretic peptide (NT‐proBNP or BNP), serum troponin T (or I), and difference between involved and uninvolved immunoglobulin free light chain values are used to classify patients into four groups of similar size; median survivals are 73, 35, 15, and 5 months. Therapy All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure. Current first‐line therapy with the best outcome is daratumumab, bortezomib, cyclophosphamide, and dexamethasone. The goal of therapy is a complete response (CR). In patients failing to achieve this depth of response options for consolidation include pomalidomide, stem cell transplantation, venetoclax, and bendamustine. Future challenges Delayed diagnosis remains a major obstacle to initiating effective therapy prior to the development of end‐stage organ failure. Trials of antibodies to catabolize deposited fibrils are underway.

show abstract

“…Several other methods are currently used, including IHC, mass spectrometry, and immunogold labelling for subtyping of amyloid. An IHC antibody panel to differentiate different amyloid proteins is considered a sensitive and reliable tool [27,28].…”

Section: Figure 2: Bar Graph Depicting the Percentage Of Types Of Amyloidosismentioning

confidence: 99%

Renal Amyloidosis: A Clinicopathological Study From a Tertiary Care Hospital in Pakistan

Ahmed¹,

Nasir²,

Moatasim³

et al. 2022

Cureus

View full text Add to dashboard Cite

IntroductionSystemic amyloidosis can affect any organ in the body, but the kidney is the most commonly involved site. It is characterized by the extracellular deposition of insoluble fibrillar proteins. Amyloid deposits can be identified histologically by Congo red stain, which gives apple-green birefringence under polarized light. Typing of renal amyloidosis is done by direct immunofluorescence on frozen tissue. The most common types of amyloidosis seen in renal tissue are amyloid light chain (AL) primary amyloidosis and amyloid A (AA) secondary amyloidosis. Although primary amyloidosis is considered the most common type in western countries, however, in the subcontinent region, secondary amyloidosis is more common.The spectrum of signs and symptoms in renal amyloidosis is variable including isolated proteinuria, nephrotic syndrome, hypertension, hypotension, and renal insufficiency. The present study aims to evaluate the incidence and aetiology of various types of renal amyloidosis, determine their distribution within the kidney, and study various clinicopathological features. ObjectiveThe present study aims to evaluate the aetiology and clinicopathological profile of renal amyloidosis, determine its various types, and their distribution within the kidney.

show abstract

Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissue

Cited by 13 publications

References 34 publications

Nodular amyloidosis of the lung presenting as lung malignancy

Nodular amyloidosis of the lung presenting as lung malignancy

Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment

Renal Amyloidosis: A Clinicopathological Study From a Tertiary Care Hospital in Pakistan

Contact Info

Product

Resources

About